Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03834506
Title Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)
Recruitment Active, not recruiting
Gender male
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

prostate adenocarcinoma

Therapies

Docetaxel + Prednisone

Dexamethasone + Docetaxel + Pembrolizumab + Prednisone

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | AUT


No variant requirements are available.